Major electrolyte abnormalities are a common toxicity of cisplatin (Loehrer et al., 1984; Von Hoff et al., 1979; Blachley et al., 1981; Vogelzang et al., 1985; Dentino et al., 1978) . Chiefly, among those is hypomagnesaemia as first described by Schilsky and Anderson in 1979 and repeatedly confirmed (Schilsky et al., 1982; Buckley et al., 1984; Lam & Adelstein, 1986; Stewart et al., 1985) , which is thought to occur as a result of renal tubular magnesium wasting (Safirstein et al., 1986) . The majority of patients affected by hypomagnesaemia show no signs or symptoms, but its manifestations can include neuromuscular irritability, weakness, confusion, seizures and ventricular arrhythmias (Vallee et al., 1960; Winkler et al., 1979; Willox et al., 1986) . Therefore, hypomagnesaemia represents a potentially serious condition.
Magnesium aspartate hydrochloride (MgAH) (Magnesiocard, Ciba-Geigy, Summit, NJ, USA) is a magnesium compound designed for oral administration in the treatment of magnesium deficiency. The intent of this randomised trial was to determine if MgAH is able to prevent and/or replenish the cisplatin-induced loss of body stores of magnesium.
Eligible patients had a histological diagnosis of locally advanced cancer of the head and neck. All patients were previously untreated, and had a performance status of <2 (CALGB). Signed informed consent was obtained from all patients. The treatment plan called for patients to receive three or four cycles of cisplatin-based neoadjuvant chemotherapy (Vokes et al., 1989 (Vokes et al., , 1990 . Entry CBC and serum chemistries were required to be within normal limits (serum magnesium > 1.6 mg dl-', 24 h creatinine clearance > 50 cm3min-'). Patients who had severe and/or persistent diarrhoea, a serum albumin of < 2.5 g dl-' or a recent history of use of magnesium containing antacids, laxatives or vitamins were ineligible for study.
Neoadjuvant chemotherapy consisted of methotrexate 120mgm-' given on day 1, followed 24h later by cisplatin 100 mg m-2 given as a 6 h intravenous infusion and a 5 day continuous infusion of 5-FU at 1,000 mg m-2day-'. Leucovorin rescue was given at 25 mg m-2 every 6 h for 6 doses on days 2 and 3 (Vokes et al., 1989 Patients in group B initially received no MgAH replacement and were followed clinically as described for group A. When patients developed hypomagnesaemia < 1.4 mg dl-' MgAH was started at 10 mEq p.o. three times daily. If serum magnesium levels did not reach 1.4 mg dl-' within 3 weeks, the dose was increased to 20 mEq of MgAH. Magnesium supplementation in group B was discontinued whenever serum magnesium levels reached 1.8 mg dl-' or greater.
At study entry and before each cycle of chemotherapy the following laboratory tests were obtained: serum electrolytes and magnesium, renal and liver function tests, and a 24 h urine for total volume, creatinine clearance, calcium, magnesium, sodium and potassium. On day 7 of each cycle the serum BUN, creatinine, magnesium, calcium, potassium and sodium were determined. Patient compliance was assessed on both study arms by counting the number of returned MgAH doses at the end of each cycle.
Comparability of the two randomised groups for presenting patient characteristics was assessed by the Fisher exact test (Siegel, 1956) for 2 x 2 tables and the Wilcoxon rank sum test (Snedecor & Cochran, 1980) for continuous data. Comparisons of the randomised groups by treatment cycle for magnesium dosage and serum magnesium levels was performed by the Wilcoxon rank sum test. Significance was set a 0.05 and all tests performed were two-sided.
Twenty-three patients were entered and randomized to treatment on this study. There were no significant differences between the randomised groups with respect to sex, age and serum chemistries at the time of study entry.
Five patients in this trial did not complete all cycles of neoadjuvant therapy: three developed chemotherapy-related complications (neutropenic fever and sepsis, severe mucositis), one refused further chemotherapy after cycle 3, and one patient expired suddenly at home following cycle 3, presumably of acute myocardial infarction. Therefore, the number of patients included in the subsequent analyses reflects the decreasing size of the patient cohort as the study progressed.
Thirteen patients randomised to group A received MgAH throughout the entire duration of the administration of neoadjuvant chemotherapy. Ten patients randomised to group B were to receive MgAH only when their serum magnesium fell to A 1.4 mg dl and this was to be discontinued when it reached or exceeded 1.8 mg dl-'. As shown in Table I , during the first two cycles of chemotherapy many patients on the intermittent arm had initial magnesium levels that did not require MgAH therapy (80% cycle 1 and 44% cycle 2). By the third cycle, however, virtually all patients in group B still on-study (89%) required MgAH and on the fourth cycle 86% required MgAH. All patients on the intermittent arm required MgAH at some point during their therapy. Additionally, of the nine patients who received at least two cycles of cisplatin therapy, seven (78%) had no discontinuation in MgAH therapy once it had been introduced into their therapy program.
Similarly, the difference in the dose of MgAH administered to patients on each arm was statistically significant only during cycle 1 (Table I) . By cycle 3 the actual MgAH dose administered to patients in both arms of this study was very similar, reflecting the fact that by cycle 3 most patients in group B were actually receiving MgAH. It is of note that no patient developed side-effects related to administration of MgAH, and diarrhoea in particular was not observed.
Serum magnesium levels were determined before each cycle of cisplatin-based chemotherapy and on day 7 (Table II) .
Only patients who received all four cycles of cisplatin and had all serum magnesium levels obtained are included in this analysis. Median magnesium levels in both groups were higher immediately before cisplatin administration compared to those on day 7 for all four cycles, indicating at least partial recovery of hypomagnesaemia with increasing time from cisplatin administration. There may also be a slight decrease in pre-cisplatin magnesium levels over time. The median magnesium concentrations were always lower in 
